Bloomage BioTechnology's (SHSE:688363) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Bloomage BioTechnology's (SHSE:688363) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The subdued market reaction suggests that Bloomage BioTechnology Corporation Limited's (SHSE:688363) recent earnings didn't contain any surprises. Our analysis suggests that along with soft profit numbers, investors should be aware of some other underlying weaknesses in the numbers.
市場反應的平淡暗示華熙生物(SHSE:688363)近期的收益並沒有帶來任何驚喜。我們的分析表明,除了利潤數字疲軟,投資者還應關注數字中的一些其他潛在弱點。

How Do Unusual Items Influence Profit?
不尋常項目如何影響利潤?
To properly understand Bloomage BioTechnology's profit results, we need to consider the CN¥78m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. If Bloomage BioTechnology doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
要正確理解華熙生物的利潤結果,我們需要考慮與非常規項目相關的7800萬CN¥的收益。我們不能否認,更高的利潤通常會讓我們對未來感到樂觀,但我們希望利潤可以持續下去。當我們分析全球絕大多數上市公司時,我們發現重大非常規項目往往不會重複。正如您所期待的那樣,這些增益被稱爲'非常規'。如果華熙生物沒有看到這種貢獻的重複,那麼在所有其他條件相等的情況下,我們預計其利潤在當前年度會下降。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能讓你想知道分析師對於未來盈利能力的預測。幸運的是,你可以點擊這裏查看一個基於他們的估算的未來盈利能力的互動圖表。
Our Take On Bloomage BioTechnology's Profit Performance
我們對華熙生物利潤表現的看法
Arguably, Bloomage BioTechnology's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Bloomage BioTechnology's true underlying earnings power is actually less than its statutory profit. Sadly, its EPS was down over the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. You'd be interested to know, that we found 3 warning signs for Bloomage BioTechnology and you'll want to know about them.
可以說,華熙生物的法定盈利因異常項目的提升而扭曲了。因此,我們認爲華熙生物的真實基礎盈利能力實際上低於其法定利潤。遺憾的是,其每股收益在過去12個月內下降了。當然,分析其盈利時我們只是觸及表面;還可以考慮利潤率、預測增長和投資回報等其他因素。請記住,在分析股票時,值得注意涉及的風險。你會感興趣地發現,我們發現了華熙生物的3個警告信號,你會想要了解這些信號。
Today we've zoomed in on a single data point to better understand the nature of Bloomage BioTechnology's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天我們聚焦於一個數據點,以更好地理解華熙生物利潤的本質。但總是有更多的發現,如果你能夠專注於細節。例如,許多人認爲高股本回報率是有利於業務經濟的跡象,而另一些人則喜歡「追蹤資金」,尋找內部人士在買入的股票。雖然這可能需要你的一些研究,但你可能會發現這一份高股本回報率公司的免費集合,或者這一份內部持股顯著的股票名單對你有幫助。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。